STAT3 and breast carcinoma: Although anti-LIFR agents do show evidence of effectively limiting primary breast tumor growth, caution should still be exercised in their use as a breast cancer therapy since inhibiting LIFR signaling could inadvertently increase metastatic outgrowth in bone where the LIFR:STAT3 pathway suppresses proliferation of disseminated breast tumor cells [32, 59–61].